These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 26095782)
1. PD-L1 expression by circulating breast cancer cells. David R Lancet Oncol; 2015 Jul; 16(7):e321. PubMed ID: 26095782 [No Abstract] [Full Text] [Related]
2. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Schalper KA; Velcheti V; Carvajal D; Wimberly H; Brown J; Pusztai L; Rimm DL Clin Cancer Res; 2014 May; 20(10):2773-82. PubMed ID: 24647569 [TBL] [Abstract][Full Text] [Related]
3. By the numbers: does circulating tumor cell enumeration have a role in metastatic breast cancer? Liu MC J Clin Oncol; 2014 Nov; 32(31):3479-82. PubMed ID: 25245442 [No Abstract] [Full Text] [Related]
4. Detection of occult metastatic breast cancer cells in blood by a multimolecular marker assay: correlation with clinical stage of disease. Taback B; Chan AD; Kuo CT; Bostick PJ; Wang HJ; Giuliano AE; Hoon DS Cancer Res; 2001 Dec; 61(24):8845-50. PubMed ID: 11751407 [TBL] [Abstract][Full Text] [Related]
5. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Abiko K; Mandai M; Hamanishi J; Yoshioka Y; Matsumura N; Baba T; Yamaguchi K; Murakami R; Yamamoto A; Kharma B; Kosaka K; Konishi I Clin Cancer Res; 2013 Mar; 19(6):1363-74. PubMed ID: 23340297 [TBL] [Abstract][Full Text] [Related]
6. Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. Wang HY; Ahn S; Kim S; Park S; Park S; Han H; Sohn JH; Kim S; Lee H Exp Mol Pathol; 2014 Dec; 97(3):445-52. PubMed ID: 25217799 [TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success. Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230 [TBL] [Abstract][Full Text] [Related]
8. Interferon-γ-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Chen J; Feng Y; Lu L; Wang H; Dai L; Li Y; Zhang P Immunobiology; 2012 Apr; 217(4):385-93. PubMed ID: 22204817 [TBL] [Abstract][Full Text] [Related]
9. CTC immune escape mediated by PD-L1. Wang X; Sun Q; Liu Q; Wang C; Yao R; Wang Y Med Hypotheses; 2016 Aug; 93():138-9. PubMed ID: 27372873 [TBL] [Abstract][Full Text] [Related]
10. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Boes M; Meyer-Wentrup F Cancer Lett; 2015 May; 361(1):49-56. PubMed ID: 25697485 [TBL] [Abstract][Full Text] [Related]
11. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Merelli B; Massi D; Cattaneo L; Mandalà M Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602 [TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Mostert B; Sleijfer S; Foekens JA; Gratama JW Cancer Treat Rev; 2009 Aug; 35(5):463-74. PubMed ID: 19410375 [TBL] [Abstract][Full Text] [Related]
13. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Soria JC; Gauthier LR; Raymond E; Granotier C; Morat L; Armand JP; Boussin FD; Sabatier L Clin Cancer Res; 1999 May; 5(5):971-5. PubMed ID: 10353728 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells and emerging blood biomarkers in breast cancer. Criscitiello C; Sotiriou C; Ignatiadis M Curr Opin Oncol; 2010 Nov; 22(6):552-8. PubMed ID: 20706122 [TBL] [Abstract][Full Text] [Related]
15. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323 [TBL] [Abstract][Full Text] [Related]
16. Presence of erbB2 mRNA in the plasma of breast cancer patients is associated with circulating tumor cells and negative estrogen and progesterone receptor status. Xu Y; Yao L; Li H; Ouyang T; Li J; Wang T; Fan Z; Lin B; Lu Y; Larsson O; Xie Y Breast Cancer Res Treat; 2006 May; 97(1):49-55. PubMed ID: 16319978 [TBL] [Abstract][Full Text] [Related]
17. [Locally advanced breast cancer (methods of treatment)]. Portnoĭ SM Vopr Onkol; 2011; 57(5):553-8. PubMed ID: 22238923 [No Abstract] [Full Text] [Related]
18. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study. Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897 [TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells in breast cancer patients using multiplex reverse transcription-polymerase chain reaction and specific primers for MGB, PTHRP and KRT19 correlation with clinicopathological features. Skondra M; Gkioka E; Kostakis ID; Pissimissis N; Lembessis P; Pectasides D; Koutsilieris M Anticancer Res; 2014 Nov; 34(11):6691-9. PubMed ID: 25368276 [TBL] [Abstract][Full Text] [Related]
20. A preliminary investigation of the relationship between circulating tumor cells and cancer stem cells in patients with breast cancer. Wang J; Cao MG; You CZ; Wang CL; Liu SL; Kai C; Dou J Cell Mol Biol (Noisy-le-grand); 2012 Feb; 58 Suppl():OL1641-5. PubMed ID: 22340707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]